Evidence map›Paper›PMID 36006050›Full record

ArticleThe Journal of urology2022

Patient-reported Outcomes After External Beam Radiotherapy With Low Dose Rate Brachytherapy Boost vs Radical Prostatectomy for Localized Prostate Cancer: Five-year Results From a Prospective Comparative Effectiveness Study.

Brian De, Dario Pasalic, Daniel A Barocas, Christopher J D Wallis, Li-Ching Huang, Zhiguo Zhao, Tatsuki Koyama, Chad Tang, Michael Goodman, Ann S Hamilton and 10 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 2 countries.

Brian DeDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3468-3359
Dario PasalicDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Daniel A BarocasDepartment of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Christopher J D WallisDivision of Urology, Department of Surgery, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Li-Ching HuangDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Zhiguo ZhaoDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Tatsuki KoyamaDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Chad TangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Michael GoodmanDepartment of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia.
Ann S HamiltonDepartment of Preventive Medicine, Keck School of Medicine at the University of Southern California, Los Angeles, California.
Xiao-Cheng WuDepartment of Epidemiology, Louisiana State University New Orleans School of Public Health, New Orleans, Louisiana.
Lisa E PaddockDepartment of Epidemiology, Cancer Institute of New Jersey, Rutgers Health, New Brunswick, New Jersey.
Antoinette StroupDepartment of Epidemiology, Cancer Institute of New Jersey, Rutgers Health, New Brunswick, New Jersey.
Matthew R CooperbergDepartment of Urology, University of California San Francisco, San Francisco, California.
Mia HashibeDepartment of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, Utah.
Brock B O'NeilDepartment of Urology, University of Utah Health, Salt Lake City, Utah.
Sherrie H KaplanDepartment of Medicine, University of California Irvine, Irvine, California.
Sheldon GreenfieldDepartment of Medicine, University of California Irvine, Irvine, California.
David F PensonDepartment of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Karen E HoffmanDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
The University of Texas MD Anderson Cancer Center · USVanderbilt University Medical Center · USRutgers, The State University of New Jersey · USUniversity of California, Irvine · USUniversity of Utah · USEmory University · USLouisiana State University · USMount Sinai Hospital · CAUniversity of California, San Francisco · USUniversity of Southern California · USVA Tennessee Valley Healthcare System · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Comparative Effectiveness of Treatments for Localized Prostate CancerR01HS019356 · AHRQ · VANDERBILT UNIVERSITY · PI PENSON, DAVID F. · 2010 to 2010
$7.6M
10-year Comparative Effectiveness and Harms of Treatments for Prostate CancerR01CA230352 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BAROCAS, DANIEL A · 2019 to 2023
$3.1M
Comparative Effectiveness of Modern Therapies for Localized Prostate CancerR01HS022640 · AHRQ · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PENSON, DAVID F. · 2013 to 2013
$1.8M
AHRQ HHS R01 HS019356AHRQ HHS R01 HS022640NCATS NIH HHS UL1 TR000445NCI NIH HHS HHSN261201800016CNCI NIH HHS HHSN261201800016INCI NIH HHS P30 CA016672NCI NIH HHS R01 CA230352
6 · The paper itself

Abstract

purposeData comparing radical prostatectomy and external beam radiation therapy with low dose rate brachytherapy boost are lacking. To better guide shared decision making regarding treatment, we compared patient reported outcomes through 5 years following radical prostatectomy or external beam radiation therapy with low dose rate brachytherapy boost for localized prostate cancer. MATERIALS AND

methodsFrom 2011-2012, men aged <80 years with localized prostate adenocarcinoma were enrolled and followed longitudinally. Patient reported outcomes included the Expanded Prostate Index Composite. Regression models adjusted for baseline scores and covariates were constructed.

resultsThe study population included 112 men treated with external beam radiation therapy with low dose rate brachytherapy boost and 1,553 treated with radical prostatectomy. Compared to radical prostatectomy, external beam radiation therapy with low dose rate brachytherapy boost was associated with clinically meaningful worse urinary irritative/obstructive (adjusted mean score difference [95% confidence interval]: 5.0 [-8.7, -1.3];

conclusionsCompared to radical prostatectomy, external beam radiation therapy with low dose rate brachytherapy boost was associated with clinically meaningful worse urinary irritative/obstructive and bowel functions but better urinary incontinence function through 5 years after treatment. These patient-reported functional outcomes may clarify treatment expectations and help inform treatment choices for localized prostate cancer.

Indexed as

BrachytherapyProstatic NeoplasmsUrinary IncontinenceHumansMalePatient Reported Outcome MeasuresProspective StudiesProstateProstatectomyQuality of Lifebrachytherapypatient reported outcome measuresprostatectomy

Identifiers

PMID36006050
PMCPMC9933910
OpenAlexW4293049207

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.